Affiliation:
1. School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411,India
2. Department of Anaesthesiology and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh 160012,India
Abstract
An infectious disease of the colon, recurrent Clostridium difficile infection
(RCDI), is hitherto considered insurmountable leading to significant morbidity
and mortality. Gut dysbiosis, generally resulting from frequent use of antibiotics,
is considered to be responsible for the etiopathogenesis of RCDI. Ironically,
the conventional treatment strategies for the disease also include the use of anti-
infective drugs such as metronidazole, vancomycin and fidaxomycin. As a result
of the efforts to overcome the limitations of these treatment options to control
the recurrence of disease, faecal microbiota transplant (FMT) has emerged as
an effective and safe alternative. It is pertinent to add here that FMT is defined as
the process of engraftment of fecal suspension from the healthy person into the
gastrointestinal tract of the diseased individual aiming at the restoration of gut microbiota.
FMT has proved to be quite successful in the treatment of recurrent and
resistant Clostridium difficile infections. In the last three decades, a lot of information
has been generated on the use of FMT for RCDI. A number of clinical
trials have been reported with generally very high success rates. However, a very
small number of patents could be found in the area, indicating that there still exists
lacuna in the knowledge about FMT with respect to its preparation, regulation,
mode of delivery and safety. The current review attempts to dive deeper to
discuss the patents available in the area while supporting the information contained
therein with the non-patent literature.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献